Equities research analysts at B. Riley started coverage on shares of Transenterix Inc (NYSEMKT:TRXC) in a note issued to investors on Friday, StockTargetPrices.com reports. The firm set a “buy” rating and a $3.00 price target on the stock. B. Riley’s target price indicates a potential upside of 75.44% from the stock’s previous close.
Transenterix (NYSEMKT:TRXC) opened at 1.71 on Friday. Transenterix has a one year low of $1.03 and a one year high of $6.10. The company’s market capitalization is $196.65 million. The firm has a 50-day moving average of $1.51 and a 200 day moving average of $2.04.
A number of hedge funds have recently made changes to their positions in the stock. National Planning Corp acquired a new stake in shares of Transenterix during the first quarter worth approximately $365,000. Geode Capital Management LLC boosted its stake in shares of Transenterix by 22.8% in the first quarter. Geode Capital Management LLC now owns 387,182 shares of the company’s stock worth $1,645,000 after buying an additional 71,972 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Transenterix during the first quarter worth approximately $133,000. Finally, State Street Corp boosted its stake in shares of Transenterix by 65.7% in the first quarter. State Street Corp now owns 684,234 shares of the company’s stock worth $2,909,000 after buying an additional 271,278 shares in the last quarter.
TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.
Receive News & Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related companies with MarketBeat.com's FREE daily email newsletter.